Hippocampal Klotho Expression Is Associated with the Neuroprotective Effects of Metformin Against ICV-STZ-Induced Cognitive Deficits.

Authors

Farzane Shanehbandpour-Tabari, Ravieh Golchoobian, Freshteh Pourabdolhossein

Published in

European journal of pharmacology. Pages 179245. Aug 14, 2026. Epub Aug 14, 2026.

Abstract

Alzheimer's disease (AD) is characterized by progressive cognitive decline, amyloid-β (Aβ) accumulation, oxidative stress, and neuroinflammation. Increasing evidence links metabolic dysfunction to AD, suggesting that antidiabetic drugs such as metformin may exert neuroprotective effects. This study investigated the effects of long-term metformin pretreatment on cognitive function, hippocampal pathology, and neuroprotective gene expression in an intracerebroventricular streptozotocin (ICV-STZ) rat model of AD. Adult male Sprague-Dawley rats were assigned to Sham, STZ, Metformin, and STZ+Metformin groups. Metformin (2 g/L in drinking water) was administered for 12 weeks before ICV-STZ injection. Spatial learning and memory were assessed using the Morris water maze. Hippocampal pathology was evaluated by H&E, Nissl, and Congo red staining, and gene expression was analyzed by quantitative PCR. ICV-STZ induced cognitive impairment, hippocampal Aβ deposition, neuronal loss, and increased expression of pro-inflammatory and oxidative stress markers. Metformin pretreatment significantly improved spatial learning and memory, reduced amyloid burden, and preserved neuronal integrity in the CA1 and CA3 regions. Metformin increased hippocampal Klotho mRNA expression, enhanced antioxidant defenses (Nrf2 and HO-1), suppressed TNF-α, IL-1β, and iNOS expression, and increased IL-10 levels. Although BDNF mRNA expression showed an upward trend, the change was not statistically significant. No significant changes in blood glucose levels were observed. In conclusion, long-term metformin pretreatment attenuated STZ-induced AD-like pathology and cognitive deficits. Its neuroprotective effects were associated with increased hippocampal Klotho expression and reduced oxidative stress and neuroinflammation, supporting further investigation of metformin and the Klotho pathway as potential preventive strategies for AD.

PMID:
42601004
Bibliographic data and abstract were imported from PubMed on 15 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.